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Abstract: Statins have a proven efficacy in lowering of plasma cholesterol and reduction of atherosclerotic 
cardiovascular disease. They also have anti-inflammatory, pro-apoptotic and anti-angiogenic effects which can be 
derived from their biochemical activity. The cell cycle could also be arrested at several stages. However, an early 
concern was the possibility of increase in malignancy. The first reports were conflicting.  
A search in Web of Science has been made with the terms “statins AND malignancy”, from 2012 to 2017.  
Twenty of 119 manuscripts were considered as useful. Manuscripts dealing with in-vitro and animal experiments were 
excluded, as well as reviews and manuscripts not related to the topic. There was a variety of malignancies under 
scrutiny. Most series showed a favorable result on either reduction of incidence in malignancy or, if a malignancy was 
diagnosed and improvement in overall or cancer specific survival. Reduction in symptoms and improvement in 
inflammatory response after adjuvant chemo and radiotherapy were documented in a few reports.  
Elimination of bias has been attempted by taking into account confounding factors or by using a propensity analysis or a 
multivariate regression. Interpreting these results is difficult due to the differences in study designs. This precluded a 
meta-analysis. The disentangling of the effect of statins on malignancy, plasma cholesterol and changes of this level in 
these patients requires a large multicenter prospective trial which might encounter ethical and logistical difficulties.  
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INTRODUCTION  
Atherosclerotic cardiovascular disease and 
malignancy are the two main conditions burdening 
health care [1]. Statins have been introduced as 
treatment of lipid disorders and have successfully 
reduced the number of cardiovascular events. 
However, some theoretical concerns have been issued 
[2]. These include non-cardiovascular events and more 
specifically a potential increase in cancer risk. A U-
shaped relationship between cholesterol – especially 
HDL – and cancer [2] and a J-shaped relation with 
mortality have been observed. The causality is still a 
matter for debate, but thus far, there is no plausible 
reason that low cholesterol is a causative factor for 
cancer. With increased longevity, competing causes for 
mortality becomes a more complex issue. Genetic lipid 
disorders give an unclear answer. 
Cancer in itself might attenuate atherosclerosis, 
based on autopsy reports. This might be clouded by 
the effect of age (as in prostate cancer), of cancer 
treatment and of cachexia. In hematological 
malignancies, especially with involved T-cells this might 
even be more present. The duration of the oncologic 
disease and reversibility of early atherosclerosis also 
might play a role. It should also be noted that there is 
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an observed discrepancy between aortic and coronary 
atherosclerosis. Therefore, this cannot be considered 
as “one homogenous disease” [1]. 
Statins act as an inhibitor of hydroxy-methyl-
glurataryl Coenzyme A (HMG CoA) reductase inhibitor, 
which is the rate-limiting step. The pleiotropic effect of 
statins can be explained by the biochemical pathways 
that are blocked. From acetate, through HMG-CoA, 
mevalonate, isopentylpyrophosphate, and geranyl 
pyrophosphate, farnesyl pyrophosphate is synthesized. 
The latter molecule is at a cross-road from which 
several pathways originate [3]. First, farnesyl 
pyrophosphate can be used to farnesylate proteins 
which play an important role is cell signaling. Second, 
from farnesyl, geranylgeranyl pyrophosphate can be 
synthesized. Geranylgeranylated proteins play a role in 
the Ras-family of proteins, and hence in the activation 
of cell surface receptors, with cell maturation, 
proliferation and migration. Third, geranylgeranyl 
pyrophosphate is a step in ubiquinone formation and 
cell respiration. Fourth, geranylgeranyl pyrophosphate 
is also a step in dolichol formation and the synthesis of 
glycoprotein. Fifth, farnesyl pyrophosphate is a step in 
the formation of squalene and hence cholesterol. This 
is a vital part of cell membranes and determines 
permeability, signal transduction and transmembrane 
exchange.  
The pleiotropic effects of statins include inhibition of 
HMG-CoA reductase (lowering LDL-cholesterol), an 
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increase in Apo B/E receptor and Apo B/E containing 
particles, promotion of apoptosis, improvement of 
endothelial cell function with inhibition of angiogenesis 
at higher dose [through inhibition of VEGF mediated 
signals], anti-inflammatory with immune modulating 
and anti-oxidant effects [3]. Because of its effects on 
the cell cycle, it might be postulated that statins could 
play a role in lower cancer rates and improved survival. 
Results, thus far seem inconsistent and there is a 
discrepancy between results of in-vitro experiments, 
animal experiments and clinical outcome. For the sake 
of simplicity, no distinction is made between lipophilic 
and hydrophilic statins, although the former have a 
lower bioavailability but the latter are less effective at. 
intracellular level  
METHODS 
A search in Web of Science has been made with 
the terms “statins AND malignancy”, from 2012 to 
2017. There were 119 hits. Forty manuscripts were not 
related to the topic. Exclusion criteria were letters to the 
Editor, meeting abstracts, reviews, meta-analysis, in-
vitro and animal experiments. Twenty articles with 
clinical results could be included. Most of the authors 
made attempts to correct for potential sources of bias 
by multivariate regression analysis or by propensity 
score analysis.  
RESULTS 
The following malignancies were under scrutiny: 
multiple myeloma [4, 5], endometrial [6, 7] and ovarian 
cancer [7], hepatocellular carcinoma [8,9], advanced 
prostate cancer [10, 11], non-small cell lung cancer 
stage IV [12], colorectal cancer [13, 14], lymphoma 
[15], renal cell carcinoma [16] and esophageal: 
squamous and adenocarcinoma [17]. Furthermore, 
transplantation related [18] and HIV related 
malignancies [19] were under scrutiny. Three 
manuscript dealt with malignancy in general and were 
based of asymptomatic persons who had purchased 
statins [20] or were in active military service [21, 22]. 
There were different approaches and designs. Six 
manuscripts were based on regional or national or 
insurance databases and national networks or 
registries [1, 4, 6, 8, 17, 20]. Five were case control 
studies [4, 7, 11, 13, 17]. There was at least four 
prospective cohort studies [6, 16, 18] and propensity 
analysis was used in several series [21, 12]. Some 
series has a specific design such as the PRIMA study, 
[15] or the phase I – open label comparison of different 
regimens of statins [23]. In one series, the effect of 
statins on survival in a specific group of patients who 
survived at least one year after cardiac transplant was 
described [18]. In another, HIV-patients were 
scrutinized [19].  
Elimination of bias was attempted, mostly by 
regression analysis with inclusion of potential 
confounders [15] such as age, BMI, ethnicity, ASA 
class and oncologic parameters [7, 11, 16, 17]. In one 
manuscript, the focus was on blood lipid level as 
source of potential bias [4, 13]. In several series, 
statins were associated with metformin [8, 9, 21] or 
angiotensin-converting enzyme inhibitors [11,18]. Two 
major outcomes were studied: the effect of statin on 
overall or disease specific survival [5-7, 10-12, 15, 16, 
18] and on cancer occurrence [4, 13, 17-21]. Few 
series addressed specific outcomes of statins such as 
the success rate of leukapheresis in patients with 
multiple myeloma [5] or the pathological response 
(according the American Joint Committee on Cancer 
grades) 0-1 v. 2-3 [5] and tissue score after 
radiotherapy [18]. These outcomes are shown in  
Table 1, with the Odds ratios (or hazard ratio) and the 
95% confidence interval.  
DISCUSSION  
The majority of the results indicated a favorable 
response of malignancy on statins, either in terms of 
disease progression and survival or on prevention, i.e. 
before the diagnosis of malignancy. This outcome has 
been observed for several malignancies as can be 
seen in the table.  
The risk of multiple myeloma in population extracted 
from large database, could be reduced by 20-28% by 
long-term use of statins [4]. Progenitor cells in patients 
with multiple myeloma were more easily mobilized 
during leukapheresis by statins in patients who suffered 
from this malignancy [5]. The incidence of 
hepatocellular carcinoma in patients with hepatitis C 
viral infection and diabetes was reduced by metformin 
(but not by insulin) and cholesterol lowering medication 
[8], but this finding did not apply to all statin / metformin 
regimens [9]. Statins improved also the overall and 
disease-specific survival after surgery for renal cell 
carcinoma [16]. Long-term use of statins was inversely 
associated with the development of esophageal 
squamous cell and adenocarcinoma [17]. The use of 
statins reduced the incidence of endometrial cancer 
(but not ovarian cancer) and improved the survival after 
diagnosis for both types, even when statins were taken 
after diagnosis [7]. Median regression grade and 
response to neo-adjuvant chemo and radio in rectal 
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cancer patients was improved by statins, but without 
improvement in oncologic outcome [14]. Statins with 
and without angiotensin converting enzyme inhibitors 
reduced digestive symptoms after pelvic radiation [18]. 
Statins in (otherwise asymptomatic) populations 
reduced cancer risk – especially hematopoietic 
malignancies [20-22]. Statins might decrease the rate 
of advanced prostate cancer and cancer mortality [11]. 
A favorable response was also documented in specific 
patient groups, with a suppressed immune system. 
Among HIV-1 treated patients, statin use was 
associated with a lower risk of cancer; the benefit was 
mainly related to AIDS-defining malignancies [19]. 
Furthermore, statins improved cancer free survival and 
overall survival in patients still living one year after 
heart transplantation [23].  
Some series found no favorable effect. No effect of 
statins on the prognosis of follicular lymphoma was 
observed [15]. The “post-diagnostic” use of statins is 
not correlated with survival of endometrium carcinoma. 
This raises the question if and when there is an optimal 
time for administering statins for this purpose [6]. 
Statins associated with Abiraterone an androgen 
synthesis inhibitor did not improve survival in 
metastatic prostate cancer. This might be due to the 
fact that both drugs compete with one another for 
transport into the cell. This raises the question of 
potential pharmacodynamical interactions of statins 
with other drugs [10]. No differences with respect to 
malignancy have been observed in otherwise healthy 
persons, but some adverse effect such as an increase 
in diabetes was observed, without concomitant 
Table 1: Effect of Statins on the Outcome  
Reference Design Cancer Outcome Result  
Epstein 2017 (4) Case control Multiple myel Prevention 20-28% reduction  
Sanni 2017 (6) Prosp. cohort Endometrial CSS 0.83 (0.64-1.08) 
Kasmari 2017 (8) Database HCV/DM/AHT HCC 0.65  
Boegemann 2016 (10) Retrospect Prostate [meta] PFS & OS 1.2 (0.4-4.2) 
Lin 2016 (12) Database  Lung stage IV CCS  OS 
0.77 (0.73-0.81) 
0.76 (0.73-0.79) 
Mansi 2016 (22) Retr. propens Healthy Malignancy no effect  
Mamtani 2016 (13) Case control Colorectal Prevention  0.98 (0.79-1.22) 
Bachy 2016 (15) PRIMA study Lymphoma EFS & OS no impact  
Chen 2015 (9) DM cohort  +/- metformin HCC Prevention  
0.32 (0.18-0.58) Simv 
0.31 (0.19-0.52) Atorv 
0.22 (0.08-0.61) Rosuv 
Kaffenberger 2015 (16) Retrospective RCC-surgery DSS  OS 
0.48 (0.28-0.83) 
0.62 (0.43-0.90) 
Galli 2014 (19) Chart study Ca in AIDS  0.45 (0.17-0.71) 
Alexandre 2015 (17) Database  case control 
Esoph (sq) 
(ad) Prevention 
0.58 (0.39 +/- 0.87) 
0.29 (0.09 +/- 0.92) 
Mace 2013 (14) Retrospective CRC Lower grade after CT+RT 2.25 (1.33-3.82) 
Lavie 2013 (7) Case control 
Ovarian 
 
Endometrial 
 
Prevention 
Survival 
Prevention 
survival 
0.56 (0.33-0.94) 
0.47 (0.26-0.85) 
0.59 (0.40-0.87) 
0.45 (0.23-0.87) 
Wedlake 2012 (23) Prospective Pelvic GI-symptoms “Reduced scores” 0.37 
Marcella 2012 (11) Case control Prostate Survival (unadj) (adj) 0.49 (0.34-0.70) 
Lutski 2012 (20) Database All  0.69 (0.55-0.88) 
Froehlich 2012 (18) Prospective After heart transplantation Prevention 0.33 (0.21-0.51) 
Ad: adenocarcinoma; adj.: adjusted; AHT: arterial hypertension; Ca: carcinoma; CSS/DSS: cancer/disease specific survival; CT: chemotherapy; DM: diabetes 
mellitus; esoph: esophageal; HCC: hepatocellular carcinoma; HCV: hepatitis C Virus; myel: myeloma; OS: overall survival; PFS: progress free survival; propens: 
propensity; retro.: retrospective; RCC: renal cell carcinoma; sq: squamous; RT: radiotherapy; unadj.: unadjusted; Ator / Rosuv / Simv: statines 
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cardiovascular beneficial effect [21, 22]. This indicates 
that statins should not be used without indication. It 
also raises the question of the duration of the treatment 
with statins. Of most interest, the risk of colorectal 
cancer was not significantly different among those who 
continued statin therapy and those who discontinued, 
but there might be an “indication bias”: the increased 
serum cholesterol was inversely related to the risk for 
colorectal cancer. The collected data, however were 
considered incomplete by the authors and there could 
have been be residual confounding. An undiagnosed 
cancer might have a cholesterol lowering effect [13]. 
This indicates that the disentangling of the association 
of statins, the level of plasma cholesterol and 
malignancy is a difficult problem. Furthermore, the 
inflammatory status could complicate the matter 
further. Atherosclerosis is largely driven by 
inflammation, but for malignancy, this seems less clear 
cut. It seems that some modulation of inflammation is a 
precondition for malignancy to thrive. Either the cancer 
itself or its treatment might diminish the inflammatory 
response. In a larger autopsy report, an inverse 
correlation between malignancy and atherosclerotic 
disease was observed. This was corroborated in a 
second analysis, derived from the SHRINE database 
[1]. However, current results confirm an earlier meta-
analysis comprising over 1,000,000 patients in 55 
manuscripts that use of statins reduced significantly all-
cause mortality (minus 30%), cancer specific mortality 
(minus 40%), progression free survival and disease 
free survival. This was consistent throughout 
stratification according subgroups (type of publication, 
type of malignancy, design of study, sample size, stage 
of the malignancy, duration of follow-up, area / country 
of study and initiation of statin treatment). Use of 
statins after diagnosis of cancer showed even a larger 
beneficial affect [24]. The current conclusion supports 
previous one that large scale prospective studies are 
needed. Prior as well as current approach are only 
hypothesis generating, while results from prospective 
studies are hypothesis confirming. The latter needs 
also a more sophisticated statistical approach since 
competing events are involved. In none of the included 
articles, except in one [19], a competing risk 
assessment according Fine and Gray has been 
performed. This has its importance in long-term studies 
of over 40 years, which are few in number [25-27]. 
However, some interesting observations have been 
made. Levels of cholesterol were inversely associated 
with colorectal cancer if the level of cholesterol was 
determined less than 6 months before the cancer 
diagnosis, but not if it was 24 months before this 
diagnosis. Statistical techniques such as propensity 
score analysis and instrumental variable analysis 
seems insufficient to solve the problem of indication 
bias [13]. An unexplained lowering of cholesterol could 
be a sign of occult colorectal cancer. This effect could 
be clouded by the use of statin, which can be 
considered as indication bias. Apart from the role of 
cholesterol, inflammatory status seems also to have an 
importance. This status is increased in atheromatosis, 
but decreased in cancer (especially with hematological 
malignancies), or by cancer treatment and in cachexia. 
Several interleukines and other inflammatory 
modulating hormones play an important role herein. It 
must be stated that these observations and theories 
were based on autopsy series [1]. In a specific 
subgroup of HIV patients, statins reduced the number 
of malignancies. Patients taking statins, however, were 
older than non-statin users and had more classical risk 
factors for cardiovascular disease and information 
about compliance was not available. In this view, 
statins had anti-inflammatory and anti-neoplastic 
activity while cholesterol – as important component of 
cell membranes played a role in the development of 
malignancy [19]. These reports indicate that there is no 
uniform view on the role of cholesterol. Furthermore, 
Kaplan-Meier analysis and Cox’ proportional hazard 
analysis are insufficient if competing events such as 
cardiovascular or cancer death are under scrutiny. A 
Fine and Gray analysis has been proposed as 
alternative. Nevertheless, these methods become more 
important with the length of the follow-up, which is 
limited to 6 years for most of the currently included 
papers.  
LIMITATIONS 
The current manuscript addresses only clinical 
results. Papers concerning the intracellular mechani- 
sms action of statins, as well as those of animal studies 
have been omitted. A meta-analysis has not been 
attempted because of the inhomogeneity of the studies. 
There is considerable variation in study design, sample 
size, tumor type, statin regimen (type, dose, timing) 
and measured outcome (reduction of potential 
malignancy v. survival after diagnosis of malignancy). 
Distinction between hydrophilic and lipophilic statins 
was not made. Current results confirm what has been 
observed earlier, but a large multicenter trial should be 
undertaken with inclusion of all possible confounders in 
order to disentangle the effects of cholesterol levels, 
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the changes of cholesterol levels and the effect of 
statins themselves. This is a major logistical endeavor. 
With current knowledge, ethical issues – withholding a 
potentially beneficial treatment – could hamper such 
enterprise.  
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